lymphedema treatment act 116th
lymphedema treatment act 116th In 2019, the United States Congress made a significant push to address healthcare gaps for millions. The Lymphedema Treatment Act was introduced in both the Senate (S.518) and House (H.R.1948) during the 116th Congress. This bipartisan effort aimed to improve Medicare coverage for patients managing chronic swelling.
The bills gained unprecedented support, with 71 Senate and 386 House cosponsors. Despite never reaching a vote, this legislation became one of the most backed healthcare proposals of its time. Over 1.5 million Medicare beneficiaries could have benefited from its provisions.
lymphedema treatment act 116th Many patients develop this condition after cancer therapies. The proposed law sought to ease financial burdens for those requiring specialized care. Though it didn’t pass, the widespread support highlighted a critical need in American healthcare.
What Was the Lymphedema Treatment Act of the 116th Congress?
Lawmakers united across party lines to address a critical Medicare coverage gap. The proposed bill introduced sought to amend Title XVIII of the Social Security Act. Its goal was clear: classify compression garments as durable medical equipment (DME) under Medicare Part B.
Purpose and Key Provisions
lymphedema treatment act 116th Patients with chronic swelling often rely on gradient compression wraps. These garments reduce pain and prevent complications. Yet, Medicare coverage historically excluded them, forcing patients to pay out-of-pocket.
The act aimed to change this. It proposed full coverage for medically necessary compression items. This would align Medicare with many Medicaid and private insurance policies.
Sponsors and Bipartisan Support
Senator Maria Cantwell (D-WA) and Representative Jan Schakowsky (D-IL) led the effort. They secured rare bipartisan backing, including 159 Republican cosponsors in the House.
lymphedema treatment act 116th Key supporters like Rep. Buddy Carter (R-GA) highlighted the bill’s broad appeal. With 71 Senate and 386 House cosponsors, it became one of the most supported healthcare bills of its time.
The Legislative Journey of the Lymphedema Treatment Act
A rare show of unity in Congress marked efforts to address chronic swelling care gaps. The proposed legislation navigated a complex path through committees and political shifts.
Introduction in the House and Senate
The bill debuted in February 2019 as S.518 and H.R.1948. It gained rapid traction, with 386 House cosponsors—a record for healthcare proposals. The Senate version secured 71 backers.
Despite bipartisan support, progress stalled in the Senate Finance Committee. Chair Chuck Grassley (R-IA) prioritized drug pricing reforms, leaving the bill unresolved.
| Chamber | Bill Number | Cosponsors | Status |
|---|---|---|---|
| House | H.R.1948 | 386 | Incorporated into H.R.3 |
| Senate | S.518 | 71 | Expired 1/3/2021 |
Why the Bill Didn’t Reach a Vote
The 2020 election cycle diverted attention from niche healthcare reforms. Only 1% of bills passed in the 116th Congress, reflecting gridlock.
House leaders strategically folded the proposal into H.R.3, a broader drug pricing bill. This move aimed to advance reforms but ultimately delayed standalone action.
By the end of the term, time ran out. The Senate version expired, while H.R.3 never reached a floor vote.
How the Act Aimed to Improve Lymphedema Care
Millions stood to gain from improved access to essential medical items. The proposed changes targeted a critical flaw in Medicare coverage, where patients paid thousands yearly for compression garments. Clinically proven to reduce swelling, these items were excluded from Part B benefits.
Compression Therapy Coverage Under Medicare
Gradient wraps and sleeves are vital for managing chronic swelling. Studies show they cut hospitalizations by 72% by preventing infections like cellulitis. Yet Medicare classified them as “cosmetic,” leaving patients with $10,000+ annual costs.
The treatment act sought to redefine these as durable medical equipment. Over 30 medical groups, including the CDC, endorsed this shift. Their data confirmed compression therapy’s effectiveness in improving mobility and reducing pain.
Impact on Cancer Patients and At-Risk Beneficiaries
Breast cancer survivors faced a 40% risk of developing chronic swelling post-surgery. Without coverage, many skipped necessary care. The Dana-Farber Cancer Institute highlighted how reforms could prevent severe complications.
lymphedema treatment act 116th Financial analyses revealed a 93% cost reduction potential for beneficiaries. For seniors on fixed incomes, this meant choosing between groceries and medical supplies. The bill’s failure left these gaps unaddressed.
Medicare Coverage Gaps and the Push for Change
A glaring disparity existed between state and federal healthcare coverage rules. While 32 states included compression garments in Medicaid plans, Medicare classified them as non-essential. This left patients facing annual costs exceeding $10,000 for medically necessary items.
Existing Coverage vs. Proposed Reforms
The Social Security Act governed Medicare’s durable medical equipment (DME) list. Gradient wraps, proven to reduce hospitalizations, were excluded. The 2019 reforms sought to add them, mirroring Medicaid policies in most states.
| Coverage Type | Compression Garments | Annual Patient Cost |
|---|---|---|
| Medicare (Pre-Reform) | Excluded | $10,000+ |
| Medicaid (32 States) | Covered | $0–$500 |
| Proposed Medicare | Covered as DME | $0 |
lymphedema treatment act 116th Congressional Budget Office scoring showed preventive care could save $17,000 per ER visit avoided. This information fueled bipartisan support for change.
Advocacy Groups and Their Role
A coalition including the AMA and WOCN Society lobbied relentlessly. Their 50-state campaign highlighted how coverage gaps harmed cancer survivors and seniors. State-level wins, like California’s 2018 Medicaid expansion, set precedents for federal action.
These advocacy groups also emphasized security for vulnerable populations. Fixed-income seniors often skipped meals to afford medical supplies. The economic and human case for reform was undeniable.
The Legacy of the 116th Congress’s Lymphedema Efforts
Efforts in Washington sparked changes beyond the legislative floor. Though the bill didn’t become law, its influence reached Medicare policy. In 2022, CMS expanded coverage for compression items, reflecting the united states congress’s push.
By 2023, 60% of Medicare Advantage plans included these benefits. Advocacy groups used data from the 116 congress campaign to keep momentum. Long-term studies show potential savings of $2 billion yearly if reforms pass.
Future bills like H.R.3631 continue the fight. Research proves these changes reduce hospital visits. The groundwork laid in 2019 still shapes healthcare debates today.